FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
Global Acute Ischemic Stroke Therapeutics Market 2020-2024
The publisher has been monitoring the acute ischemic stroke therapeutics market and it is poised to grow by $ 1.22 bn during 2020-2024, progressing at a CAGR of 5% during the forecast period. The reports on the acute ischemic stroke therapeutics market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of stroke, increasing adoption of NOACs, and increasing prevalence of sedentary lifestyles. In addition, the rising prevalence of stroke is anticipated to boost the growth of the market as well.
The acute ischemic stroke therapeutics market analysis includes type segment and geographical landscapes.
The acute ischemic stroke therapeutics market is segmented as below:
By Type
The acute ischemic stroke therapeutics market report covers the following areas:
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
The publisher has been monitoring the acute ischemic stroke therapeutics market and it is poised to grow by $ 1.22 bn during 2020-2024, progressing at a CAGR of 5% during the forecast period. The reports on the acute ischemic stroke therapeutics market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of stroke, increasing adoption of NOACs, and increasing prevalence of sedentary lifestyles. In addition, the rising prevalence of stroke is anticipated to boost the growth of the market as well.
The acute ischemic stroke therapeutics market analysis includes type segment and geographical landscapes.
The acute ischemic stroke therapeutics market is segmented as below:
By Type
- Thrombolytics
- Anticoagulants
- Antiplatelets
- Antihypertensives
- Other therapeutics
- North America
- Europe
- Asia
- ROW
The acute ischemic stroke therapeutics market report covers the following areas:
- Acute ischemic stroke therapeutics market sizing
- Acute ischemic stroke therapeutics market forecast
- Acute ischemic stroke therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
Executive Summary
- Market Overview
- Market ecosystem
- Market characteristics
- Value chain analysis
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segments
- Comparison by Type
- Thrombolytics - Market size and forecast 2019-2024
- Anticoagulants - Market size and forecast 2019-2024
- Antiplatelets - Market size and forecast 2019-2024
- Antihypertensives - Market size and forecast 2019-2024
- Other therapeutics - Market size and forecast 2019-2024
- Market opportunity by Type
- Customer landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
- Vendor landscape
- Landscape disruption
- Competitive Scenario
- Vendors covered
- Market positioning of vendors
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2019 - 2024 ($ million)
- Global market: Year-over-year growth 2019 - 2024 (%)
- Five forces analysis 2019 & 2024
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2019
- Type - Market share 2019-2024 (%)
- Comparison by Type
- Thrombolytics - Market size and forecast 2019-2024 ($ million)
- Thrombolytics - Year-over-year growth 2019-2024 (%)
- Anticoagulants - Market size and forecast 2019-2024 ($ million)
- Anticoagulants - Year-over-year growth 2019-2024 (%)
- Antiplatelets - Market size and forecast 2019-2024 ($ million)
- Antiplatelets - Year-over-year growth 2019-2024 (%)
- Antihypertensives - Market size and forecast 2019-2024 ($ million)
- Antihypertensives - Year-over-year growth 2019-2024 (%)
- Other therapeutics - Market size and forecast 2019-2024 ($ million)
- Other therapeutics - Year-over-year growth 2019-2024 (%)
- Market opportunity by Type
- Customer landscape
- Market share by geography 2019-2024 (%)
- Geographic comparison
- North America - Market size and forecast 2019-2024 ($ million)
- North America - Year-over-year growth 2019-2024 (%)
- Europe - Market size and forecast 2019-2024 ($ million)
- Europe - Year-over-year growth 2019-2024 (%)
- Asia - Market size and forecast 2019-2024 ($ million)
- Asia - Year-over-year growth 2019-2024 (%)
- ROW - Market size and forecast 2019-2024 ($ million)
- ROW - Year-over-year growth 2019-2024 (%)
- Key leading countries
- Market opportunity by geography ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Amgen Inc. - Overview
- Amgen Inc. - Business segments
- Amgen Inc. - Key offerings
- Amgen Inc. - Key customers
- Amgen Inc. - Segment focus
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key offerings
- Bayer AG - Key customers
- Bayer AG - Segment focus
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Business segments
- Boehringer Ingelheim International GmbH - Key offerings
- Boehringer Ingelheim International GmbH - Key customers
- Boehringer Ingelheim International GmbH - Segment focus
- Bristol-Myers Squibb Co. - Overview
- Bristol-Myers Squibb Co. - Product and service
- Bristol-Myers Squibb Co. - Key offerings
- Bristol-Myers Squibb Co. - Key customers
- Bristol-Myers Squibb Co. - Segment focus
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Key customers
- Daiichi Sankyo Co. Ltd. - Segment focus
- F. Hoffmann-La Roche Ltd. - Overview
- F. Hoffmann-La Roche Ltd. - Business segments
- F. Hoffmann-La Roche Ltd. - Key offerings
- F. Hoffmann-La Roche Ltd. - Key customers
- F. Hoffmann-La Roche Ltd. - Segment focus
- Merck & Co. Inc. - Overview
- Merck & Co. Inc. - Business segments
- Merck & Co. Inc. - Key offerings
- Merck & Co. Inc. - Key customers
- Merck & Co. Inc. - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Sanofi - Overview
- Sanofi - Business segments
- Sanofi - Key offerings
- Sanofi - Key customers
- Sanofi - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
The publisher recognizes the following companies as the key players in the global acute ischemic stroke therapeutics market: Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., and Sanofi.
Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is TBI, a value-addition in AIS research.'
According to the report, one of the major drivers for this market is the rising prevalence of stroke.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is TBI, a value-addition in AIS research.'
According to the report, one of the major drivers for this market is the rising prevalence of stroke.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi
Note: Product cover images may vary from those shown
LOADING...